Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians
Therapeutic Drug Monitoring, Volume 27, No. 3, Year 2005
Notification
URL copied to clipboard!
Description
Arylamine N-acetyl transferase (NAT2) displays extensive genetic polymorphisms that affect the rates of acetylation of drugs and genotoxic compounds such as amine carcinogens. To investigate whether the slow acetylator genotype is a risk factor for development of bladder cancer following schistosomal infection of the urinary tract, the authors determined the frequencies of 3 common polymorphisms in the NAT2 gene (341T>C, 590G>A, and 282>T), which are associated with impaired acetylation activity, in control subjects (n = 61; mean age 34.3 ± 9.2 years) and in schistosomiasis-associated bladder cancer patients (n = 55; 52 ± 10.9 years) from the Egyptian population. Genotyping was carried out using rapid cycle PCR on the LightCycler, and subjects were assigned to a slow, intermediate, or rapid acetylator phenotype on the basis of the genotypes. The frequencies of the mutant alleles observed in the controls from the present study were similar to those reported previously for both the Egyptian population and other Arab populations. Patients showed a higher prevalence (78.2%) of slow acetylator phenotype than controls (67.2%), but this did not reach statistical significance (P = 0.19). However, there were significantly more individuals who were carriers of 2 mutant 341T>C alleles (NAT2*5/*5 genotype) in the patient group compared with controls (odds ratio 2.6, CI 1.02-6.67, P = 0.026). The alloenzyme encoded by this allele has been shown to display a large reduction in its catalytic activity. In conclusion, these data suggest that the NAT2*5/*5 genotype is a potential risk factor for development of urinary bladder cancer in patients with prior schistosomiasis infection. Copyright © 2005 by Lippincott Williams & Wilkins.
Authors & Co-Authors
El Desoky, Ehab S.
Egypt, Asyut
Assiut University
Egypt, Asyut
Faculty of Medicine
Abdelsalam, Yasser Mahmoud
Egypt, Asyut
Faculty of Medicine
Salama, Ragaa H.M.
Egypt, Asyut
Assiut University
el-Akkad, Magdy A.
Egypt, Asyut
Faculty of Medicine
Atanasova, Srebrena
Germany, Gottingen
Georg-august-universität Göttingen
Von Ahsen, Nicolas
Germany, Gottingen
Georg-august-universität Göttingen
Armstrong, Victor W.
Germany, Gottingen
Georg-august-universität Göttingen
Oellerich, Michael
Germany, Gottingen
Georg-august-universität Göttingen
Statistics
Citations: 20
Authors: 8
Affiliations: 3
Identifiers
Doi:
10.1097/01.ftd.0000164197.95494.aa
ISSN:
01634356
Research Areas
Cancer
Genetics And Genomics
Health System And Policy
Infectious Diseases
Study Design
Cross Sectional Study
Case-Control Study